

## Supplemental Online Content

Bitar C, Ninh T, Brag K, et al. Apremilast in recalcitrant cutaneous dermatomyositis. *JAMA Dermatol*. Published online October 5, 2022. doi:10.1001/jamadermatol.2022.3917

**eTable 1.** Immunohistochemical Staining Technique

**eTable 2.** Adverse Events After Apremilast

**eFigure 1.** Flow Chart

**eFigure 2.** Absolute Change in Cutaneous Disease Activity Severity Index Score by Patient at 3 mo Into Apremilast Therapy

**eFigure 3.** Chemokine (C-C Motif) Ligand 5 (CCL5) Level Before and 3 mo After


This supplemental material has been provided by the authors to give readers additional information about their work.

Antibody	Vendor	Antigen Retrieval	Dilution	Time (Room Temperature)
CCL5/RANTES	Invitrogen/Fisher, Cat# 710001	Dako Envision Flex TRS, Low pH	1:1600	60 mins
phospho- STAT1	Cell Signaling Technology, Cat# 9167	Dako Envision Flex TRS, High pH	1:75	60 mins
phospho- STAT3	Cell Signaling Technology, Cat# 9145	Dako Envision Flex TRS, High pH	1:100	60 mins


**eTable 1.** Immunohistochemical Staining Technique

Adverse Event	Grade 1-2	Grade 3-5
Headache	7 (87.5%)	0
Nausea	5 (62.5%)	0
Diarrhea	4 (50%)	0
Herpes Zoster	2 (25%)	0
Influenza	1 (12.5%)	0
Pneumonia	1 (12.5%)	0
Acute sinusitis	1 (12.5%)	0
Hypertension	1 (12.5%)	0
Ocular Pressure	1 (12.5%)	0

**eTable 2.** Adverse Events After Apremilast  
CTCAE version 5.0.




**eFigure 1.** Flow Chart




**eFigure 2.** Absolute Change in Cutaneous Disease Activity Severity Index Score by Patient at 3 mo Into Apremilast Therapy


A



B



C



**eFigure 3.** Chemokine (C-C Motif) Ligand 5 (CCL5) Level Before and 3 mo After Apremilast

**A.** No significant change in CCL5 immunostain on frozen section of patient 2 skin biopsies before and 3 months post apremilast. (original magnification x200). **B-C.** Paired analysis change in CCL5 percent positive cells and H score at baseline and 3 months post apremilast.